NVR 3-778, a First-in-Class HBV Core Inhibitor, Alone and in Combination with Peg-Interferon (PegIFN), in Treatment-Naive HBeAg-Positive Patients: Early Reductions in HBV DNA and H... by Yuen, M.-F, Kim, D.J, Weilert, F, Chan, H.L.-Y, Lalezari, J.P, Hwang, S.G, Nguyen, T, Liaw, S, Brown, N, Klumpp, K, Flores, O, Hartman, G, Gane, E

Get full text

845 ONCE DAILY SOFOSBUVIR PLUS RIBAVIRIN FOR 12 AND 24 WEEKS IN TREATMENT-NAÏVE PATIENTS WITH HCV INFECTION: THE QUANTUM STUDY by Lalezari, J.P, Nelson, D.R, Hyland, R.H, Lin, M, Rossi, S.J, Symonds, W.T, Rodriguez-Torres, M, Lawitz, E.J

Get full text

7 PSI-7977 PROTON AND ELECTRON: 100% CONCORDANCE OF SVR4 WITH SVR24 IN HCV GT1, GT2, & GT3 by Lawitz, E, Gane, E, Stedman, C, Lalezari, J.P, Hassanein, T, Kowdley, K.V, Poordad, F.F, Sheikh, A.M, Afdal, N.H, Bernstein, D.E, DeJesus, E, Freilich, B, Nelson, D.R, Dieterich, D.T, Jacobson, I.M, Jensen, D, Abrams, G.A, Darling, J.M, Rodriguez-Torres, M, Reddy, K.R, Sulkowski, M.S, Bzowej, N.H, DeMicco, M.P, Strohecker, J.S, Hyland, R.H, Anderson, J.K, Baker, C, Kirven, S, Hindes, R.G, Albanis, E, Symonds, W.T, Berrey, M.M

Get full text

LB06 - NVR 3-778, a First-in-Class HBV Core Inhibitor, Alone and in Combination with Peg-Interferon (PegIFN), in Treatment-Naive HBeAg-Positive Patients: Early Reductions in HBV DN... by Yuen, M.-F., Kim, D.J., Weilert, F., Chan, H.L.-Y., Lalezari, J.P., Hwang, S.G., Nguyen, T., Liaw, S., Brown, N., Klumpp, K., Flores, O., Hartman, G., Gane, E.

Get full text